Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday. The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use. The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said. In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease. |
Woman, 38, screamed 'my leg, my leg' after being hit by stray bullet in Stamford Hill 'driveSteady on Joe! Biden, 81, catches himself after tripping on a step againDeliveroo transports food to customers in west London on penny farthing bicycle from 1880sThe top UN court is holding hearings on the Israeli military's incursion into RafahAll eyes are on Coppola in Cannes. Sound familiar?Kervin Arriaga scores for the second straight game and Minnesota United ties the LA Galaxy 2Europe on the edge as assassination attempt on pro42 rescued and 3 still missing after migrant boat sends distress signal south of GreeceNew Kansas abortion clinic will open to help meet demand from restrictive neighboring statesEurope on the edge as assassination attempt on pro